Jifeng Feng

Jiangsu Cancer Hospital - Department of Medical Oncology

Nanjing

China

Nanjing Medical University - Jiangsu Institute of Cancer Research

Nanjing

China

Nanjing Medical University - Affiliated Cancer Hospital

Nanjing

China

SCHOLARLY PAPERS

6

DOWNLOADS

136

SSRN CITATIONS

3

CROSSREF CITATIONS

0

Scholarly Papers (6)

1.

Nivolumab versus Docetaxel in a Predominantly Chinese Patient Population with Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 078 Randomised Phase 3 Clinical Trial

Number of pages: 31 Posted: 25 Sep 2018
Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Shanghai Jiao Tong University (SJTU), Jilin Cancer Hospital, Tongji University - Department of Medical Oncology, Chinese Academy of Sciences (CAS), The Chinese University of Hong Kong (CUHK), Sun Yat-Sen University (SYSU), Guangdong Academy of Medical Sciences, Central South University - Hunan Cancer Hospital, Jiangsu Cancer Hospital - Department of Medical Oncology, Zhejiang Cancer Hospital, Leningrad Regional Clinical Hospital, Zhejiang University, Zhengzhou University - Henan Cancer Hospital, Sichuan University - West China Hospital, Central South University, Chinese Academy of Medical Sciences - Peking Union Medical College, Bristol-Myers Squibb, Bristol-Myers Squibb and Fudan University
Downloads 50 (406,789)
Citation 2

Abstract:

Loading...

nivolumab; PD-1 inhibitor; non-small-cell lung cancer; NSCLC; China; docetaxel; immunotherapy

2.

Pyrotinib or Lapatinib Combined with Capecitabine in Women with HER2-Positive Metastatic Breast Cancer Previously Treated with Taxanes, Anthracyclines, And/Or Trastuzumab: An Open-Label, Randomised, Phase 2 Study

Number of pages: 111 Posted: 22 Nov 2018
Chinese Academy of Medical Sciences - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Chinese Academy of Medical Sciences - Peking Union Medical College, Jilin University (JLU) - First Affiliated Hospital, Academy of Military Sciences - Academy of Military Medical Sciences, Tianjin Medical University, Hebei Medical University, Peking University - Cancer Hospital and Institute, Huazhong University of Science and Technology (Formerly Tongi Medical University), Jiangsu Cancer Hospital - Department of Medical Oncology, Sun Yat-Sen University (SYSU) - Cancer Center, Fudan University - Shanghai Cancer Center (FUSCC), Jiangsu Hengrui Medicine Co., Ltd. and Jiangsu Hengrui Medicine Co., Ltd.
Downloads 42 (436,598)
Citation 1

Abstract:

Loading...

Pyrotinib, lapatinib, HER2-positive metastatic breast cancer

3.

Anlotinib for Previously Treated Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ALTER1102): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial

Number of pages: 26 Posted: 28 Jul 2019
Chinese Academy of Medical Sciences - Cancer Hospital, Xi'an Jiaotong University (XJTU) - First Affiliated Hospital, Shanghai Jiao Tong University (SJTU) - Shanghai Chest Hospital, Xinxiang Medical University - First Affiliated Hospital, Zhengzhou University - First Affiliated Hospital, Nanjing Medical University - First Affiliated Hospital, Jiangsu Cancer Hospital - Department of Medical Oncology, Shandong University - Shandong Cancer Hospital, Tianjin Cancer Hospital, Nanjing Medical University - Department of Biostatistics, Zhengzhou University - Henan Cancer Hospital, Chinese Academy of Medical Sciences - Peking Union Medical College Hospital, Harbin Medical University - Cancer Hospital, Xinjiang Medical University - Affiliated Tumor Hospital, Chinese Academy of Medical Sciences - Department of Medical Oncology and National Cancer Center, Korea - Department of Thoracic Surgical Oncology
Downloads 21 (540,576)

Abstract:

Loading...

esophageal squamous cell carcinoma; metastatic; anlotinib; survival; progression-free survival; adverse events

4.

Chidamide Plus Exemestane for Postmenopausal Patients with Hormone-Receptor-Positive Advanced Breast Cancer (ACE Study): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial

Number of pages: 90 Posted: 05 Feb 2019
Chinese PLA General Hospital, Fifth Medical Centre, Jilin University (JLU) - First Affiliated Hospital, Fudan University - Shanghai Cancer Center (FUSCC), Harbin Medical University - Cancer Hospital, Liaoning Cancer Hospital & Institute, Zhengzhou University - Henan Cancer Hospital, Sun Yat-Sen University (SYSU) - Cancer Center, Central South University - Hunan Cancer Hospital, Jiangsu Province People's Hospital, Tumour Hospital of Hebei Province, Tianjin Medical University, Jilin Cancer Hospital, Anhui Provincial Hospital, Shandong University - Jinan Central Hospital, Third Hospital of Nanchang, Beijing Cancer Hospital, Anhui Medical University - First Affiliated Hospital, Jiangsu Cancer Hospital - Department of Medical Oncology, Zhejiang Cancer Hospital, Peking University - Shenzhen Hospital, Fudan University, Zhongshan Hospital, Department of Oncology, Cangzhou Central Hospital, Northwestern University - Feinberg School of Medicine, Chipscreen Biosciences Ltd and Chipscreen Biosciences Ltd
Downloads 17 (565,234)

Abstract:

Loading...

Chidamide; Histone deacetylase inhibitor; Exemestane; Hormonereceptor- positive; Advanced breast cancer; Phase 3 trial

5.

Randomized Controlled Trial of Irinotecan Plus S-1 for Pretreated Patients with Advanced Esophageal Squamous Cell Carcinoma

Number of pages: 66 Posted: 24 Sep 2018
Chinese Academy of Medical Sciences - Cancer Hospital, Chinese Academy of Medical Sciences - Peking Union Medical College, Zhengzhou University - Henan Cancer Hospital, Chinese Academy of Medical Sciences - Peking Union Medical College, Xinxiang Medical University - First Affiliated Hospital, Tianjin Cancer Hospital, Central South University - Hunan Cancer Hospital, Harbin Medical University - Cancer Hospital, Shandong University - Shandong Cancer Hospital, Jiangsu Cancer Hospital - Department of Medical Oncology, Jilin Cancer Hospital, Shanxi Cancer Hospital, Shanxi Cancer Hospital, Huazhong University of Science and Technology (Formerly Tongi Medical University) - Tongji Hospital, Chifeng Municipal Hospital, Central South University - Second Xiangya Hospital, Zhengzhou University - First Affiliated Hospital and Chinese Academy of Medical Sciences - Peking Union Medical College
Downloads 4 (652,099)

Abstract:

Loading...

Esophageal Squamous Cell Carcinoma; Irinotecan; S-1

6.

FOX-A1 Contributes to Acquisition of Chemoresistance in Human Lung Adenocarcinoma via Transactivation of SOX5

10.1016/j.ebiom.2019.05.046
Number of pages: 53 Posted: 09 Apr 2019
Jiangsu Cancer Hospital - Department of Medical Oncology, Nanjing University - Medical School, Jiangsu Cancer Hospital - Department of Medical Oncology, Soochow University - Department of Medical Oncology, Wake Forest University - Institute for Regenerative Medicine, Jiangsu Cancer Hospital - Department of Medical Oncology, Nanjing University - Medical School, Soochow University - Department of Medical Oncology, Soochow University - Department of Medical Oncology and Jiangsu Cancer Hospital - Department of Medical Oncology
Downloads 2 (669,453)

Abstract:

Loading...

lung adenocarcinoma; chemoresistance; FOX-A1; SOX5